Abstracts tagged "giant cell arteritis"

Abstract Number: 2651 • 2019 ACR/ARP Annual Meeting
Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?
Berkan Armagan ¹, Abdullah Yildirim ², Alper Sarı ³, Bayram Farisoğulları ³, Emre Bilgin ³, Levent Kilic ⁴, Umut Kalyoncu ⁵, Şule Apras Bilgen ⁴ and Omer Karadag⁶, ¹Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ³Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ⁴Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey, ⁶Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey
Background/Purpose: In parallel to the improvements in imaging, increasing data is accumulated regarding phenotypes of primary vasculitides. Giant cell arteritis (GCA) is a large vessel…
Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Aladdin Mohammad¹, Pavlos Stamatis ¹ and Aleksandra Turkiewicz ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
Abstract Number: 2921 • 2019 ACR/ARP Annual Meeting
High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis
Christine rodriguez ¹, Wagih Ben Hassen ¹, Pierre Seners ², Catherine Oppenheim ¹ and Alexis Régent³, ¹Département d’imagerie, pôle Neuro Sainte Anne, GHT Paris – Psychiatrie & Neurosciences, 1 rue Cabanis, 75014 Paris, Paris, Ile-de-France, France, ²Service de neurologie, pôle Neuro Sainte Anne, GHT Paris – Psychiatrie & Neurosciences, 1 rue Cabanis, 75014 Paris, Paris, Ile-de-France, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis of large arteries affecting people older than 50 years. Temporal artery biopsy (TAB)…
Abstract Number: 2652 • 2019 ACR/ARP Annual Meeting
Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up
Elena Galli¹, Francesco Muratore ², Luigi Boiardi ³, Alberto Cavazza ⁴, Giovanna Restuccia ², Luca Cimino ⁵ and Carlo Salvarani ⁶, ¹Division of Rheumatology, University of Modena and Reggio Emilia, Modena, Italy, ²Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Pathology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵Ophthalmology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁶Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases, inflammation…
Abstract Number: 2677 • 2019 ACR/ARP Annual Meeting
Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Aladdin Mohammad¹, Aleksandra Turkiewicz ², Pavlos Stamatis ¹, Carl Turesson ³, Martin Englund ² and Ali Kiadaliri ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: To study the healthcare resource utilization (HRU) in patients with giant cell arteritis (GCA) compared with the background population in southern Sweden.Methods: The study…
Abstract Number: 2923 • 2019 ACR/ARP Annual Meeting
Clinical Subsets in Giant Cell Arteritis
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Richard Watts ⁶, Raashid Luqmani ³, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Giant cell arteritis (GCA) is a clinically heterogeneous disease. Disease subsets based upon cranial versus extracranial artery involvement have been proposed. The study objective…
Abstract Number: 2655 • 2019 ACR/ARP Annual Meeting
Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment
Eugenio de Miguel¹, Irene Monjo ², Elisa Fernández ³, Diana Peiteado ⁴, Chamaida Plasencia ⁵ and Alejandro Balsa ⁵, ¹Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ³Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. In the EULAR recommendations of 2018 for the use of imaging…
Abstract Number: 2678 • 2019 ACR/ARP Annual Meeting
Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms
Mónica Calderón-Goercke¹, Javier Loricera ², DIANA PRIETO- PENA ³, Santos Castañeda ⁴, Vicente Aldasoro Caceres ⁵, Ignacio Villa ⁶, Alicia Humbría ⁷, Clara Moriano ⁸, Susana Romero-Yuste ⁹, Javier Narváez ¹⁰, Catalina Gómez-Arango ¹¹, Eva Perez Pampín ¹², Rafael Melero ¹³, Elena Becerra-Fernández ¹⁴, Marcelino Revenga ¹⁵, Noelia Álvarez-Rivas ¹⁶, Carles Galisteo ¹⁷, Francisca Sivera ¹⁸, Alejandro Olivé-Marqués ¹⁹, María Álvarez del buergo ²⁰, Luisa Marena-Rojas ²¹, Carlos Fernández-López ²², Francisco Navarro ²³, E. Raya ²⁴, Eva Galindez-Agirregoikoa ²⁵, Beatriz Arca ²⁶, Roser Solans-Laqué ²⁷, Arantxa Conesa ²⁸, Cristina Hidalgo ²⁹, Carlos Vazquez ³⁰, Jose Andrés Román-Ivorra ³¹, Pau Lluch ³², Sara Manrique ³³, P. Vela ³⁴, Eugenio de Miguel ³⁵, Carmen Torres-Martín ³⁶, Juan Carlos Nieto ³⁷, Carmen Ordas-Calvo ³⁸, Eva salgado-Pérez ³⁹, Cristina Luna-Gómez ⁴⁰, F. Javier Toyos-Sáenz De Miera ⁴¹, Nagore Fernández-Llanio ⁴², Antonio García ⁴³, Carmen Larena ⁴⁴, María Varela-García ⁵, Raquel Dos Santos ⁴⁵, Norberto Ortego ⁴⁶, Jose Luis Hernández ¹, Miguel Angel González-Gay ⁴⁷ and Ricardo Blanco ⁴⁸, ¹Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Hospital de La Princesa, Madrid, Madrid, Spain, ⁸Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ¹¹Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ¹²Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹³Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁴Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramón y Cajal, Madrid, Madrid, Spain, ¹⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ¹⁷Hospital Parc Taulí, Barcelona, Catalonia, Spain, ¹⁸Hospital General Universitario de Elda, Elda, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ²⁰Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ²¹Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ²²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²³Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, ²⁴Hospital San Cecilio, Granada, Andalucia, Spain, ²⁵Hospital de Basurto, Bilbao, Pais Vasco, Spain, ²⁶Hospital Universitario San Agustín, Avilés, Asturias, Spain, ²⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ²⁸Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, ²⁹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³⁰Hospital Miguel Servet, Zaragoza, Aragon, Spain, ³¹Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ³²Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, ³³Hospital Regional de Málaga, Málaga, Andalucia, Spain, ³⁴Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ³⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ³⁶Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁷Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, ³⁸Hospital Cabueñes, Gijón, Asturias, Spain, ³⁹Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ⁴⁰Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, ⁴¹Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, ⁴²Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, ⁴³Hospital Virgen de las Nieves, Granada, Andalucia, Spain, ⁴⁴Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴⁵Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Galicia, Spain, ⁴⁶Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, Granada, Spain, ⁴⁷Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁸Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: In Giant Cell Arteritis (GCA) two dominant cytokine clusters have been linked to disease activity, IL-6 – IL-17 axis (Th17) and IL-12 – IFN…
Abstract Number: 2656 • 2019 ACR/ARP Annual Meeting
The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy
Sarah Chung¹, Meredith Morcos ², Scott Pollock ¹ and Bernard Ng ³, ¹University of Washington Division of Rheumatology, Seattle, WA, ²University of Washington Division of Rheumatology, Seattle, ³University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, WA
Background/Purpose: This study aimed to identify the incidence of ophthalmic complication of giant cell arteritis (GCA) among subjects with negative temporal artery biopsy (TAB) and to…
Abstract Number: 2679 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
Mónica Calderón-Goercke¹, Javier Loricera ², DIANA PRIETO- PENA ³, Santos Castañeda ⁴, Vicente Aldasoro Caceres ⁵, Ignacio Villa ⁶, Alicia Humbría ⁷, Clara Moriano ⁸, Susana Romero-Yuste ⁹, Javier Narváez ¹⁰, Catalina Gómez-Arango ¹¹, Eva Perez Pampín ¹², Rafael Melero ¹³, Elena Becerra-Fernández ¹⁴, Marcelino Revenga ¹⁵, Noelia Álvarez-Rivas ¹⁶, Carles Galisteo ¹⁷, Francisca Sivera ¹⁸, Alejandro Olivé-Marqués ¹⁹, María Álvarez del buergo ²⁰, Luisa Marena-Rojas ²¹, Carlos Fernández-López ²², Francisco Navarro ²³, E. Raya ²⁴, Eva Galindez-Agirregoikoa ²⁵, Beatriz Arca ²⁶, Roser Solans-Laqué ²⁷, Arantxa Conesa ²⁸, Cristina Hidalgo ²⁹, Carlos Vazquez ³⁰, Jose Andrés Román-Ivorra ³¹, Pau Lluch ³², Sara Manrique ³³, P. Vela ³⁴, Eugenio de Miguel ³⁵, Carmen Torres-Martín ³⁶, Juan Carlos Nieto ³⁷, Carmen Ordas-Calvo ³⁸, Eva salgado-Pérez ³⁹, Cristina Luna-Gómez ⁴⁰, F. Javier Toyos-Sáenz De Miera ⁴¹, Nagore Fernández-Llanio ⁴², Antonio García ⁴³, Carmen Larena ⁴⁴, María Varela-García ⁵, Elena Aurrecoechea ⁶, Francisco Ortiz-Sanjuán ³¹, Jose Luis Hernández ¹, Miguel Angel González-Gay ⁴⁵ and Ricardo Blanco ⁴⁶, ¹Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Hospital de La Princesa, Madrid, Madrid, Spain, ⁸Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ¹¹Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ¹²Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹³Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁴Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramón y Cajal, Madrid, Madrid, Spain, ¹⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ¹⁷Hospital Parc Taulí, Barcelona, Catalonia, Spain, ¹⁸Hospital General Universitario de Elda, Elda, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ²⁰Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ²¹Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ²²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²³Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, ²⁴Hospital San Cecilio, Granada, Andalucia, Spain, ²⁵Hospital de Basurto, Bilbao, Pais Vasco, Spain, ²⁶Hospital Universitario San Agustín, Avilés, Asturias, Spain, ²⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ²⁸Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, ²⁹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³⁰Hospital Miguel Servet, Zaragoza, Aragon, Spain, ³¹Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ³²Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, ³³Hospital Regional de Málaga, Málaga, Andalucia, Spain, ³⁴Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ³⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ³⁶Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁷Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, ³⁸Hospital Cabueñes, Gijón, Asturias, Spain, ³⁹Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ⁴⁰Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, ⁴¹Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, ⁴²Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, ⁴³Hospital Virgen de las Nieves, Granada, Andalucia, Spain, ⁴⁴Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴⁵Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Recently, based on the GiACTA trial results, weekly subcutaneous Tocilizumab (TCZ) has been approved for the treatment of Giant Cell Arteritis (GCA). It has…
Abstract Number: 108 • 2019 ACR/ARP Annual Meeting
Mucosal Associated Invariant T Cells in Giant Cell Arteritis
Thibault Ghesquière¹, Marion Ciudad ², Hélène Greigert ², Claire Gerard ², Claudie Cladière ², Marine Thebaut ², Alexandre Guilhem ³, Vanessa Leguy-Seguin ³, Sabine Berthier ³, Nicolas Falvo ³, Barbara Nicolas ³, Thibault Maillet ³, herve devilliers ⁴, Philip Bielefeld ⁴, Nathalie Vernier ⁵, François Maurier ⁵, Paul Ornetti ⁶, Valérie Quipourt ⁷, Pierre-Henry Gabrielle ⁸, Catherine Creuzot-Garcher ⁸, Laurent Martin ⁹, Sylvain Audia ¹, Bernard Bonnotte ¹ and Maxime Samson ¹, ¹Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ²Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ³Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon, Dijon, France, ⁴University Hospital Dijon, internal medicine and systemic diseases, Dijon, Bourgogne, France, ⁵Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁶Department of rheumatology, INSERM 1093 CAPS, Dijon University Hospital, Dijon, France, ⁷Service de Médecine Interne Gériatrie, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon, Dijon, France, ⁸Service d’Ophtalmologie, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon, Dijon, France, ⁹Laboratoire d’anatomie et cytologie pathologiques, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon, Dijon, France
Background/Purpose: Mucosal Associated Invariant T (MAIT) cells express a semi invariant T-cell receptor (TCR) (TCRVα7.2) restricted to MHC related protein 1 (MR1) and are able…
Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Salman Mahmood¹, Yuanyuan Ji ², Yi Peng ² and Zaki Abou Zahr ¹, ¹Hennepin Healthcare, Minneapolis, MN, ²Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
Abstract Number: 2681 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Mónica Calderón-Goercke¹, Javier Loricera ², DIANA PRIETO- PENA ³, Santos Castañeda ⁴, Vicente Aldasoro Caceres ⁵, Ignacio Villa ⁶, Alicia Humbría ⁷, Clara Moriano ⁸, Susana Romero-Yuste ⁹, Javier Narváez ¹⁰, Catalina Gómez-Arango ¹¹, Eva Perez Pampín ¹², Rafael Melero ¹³, Elena Becerra-Fernández ¹⁴, Marcelino Revenga ¹⁵, Noelia Álvarez-Rivas ¹⁶, Carles Galisteo ¹⁷, Francisca Sivera ¹⁸, Alejandro Olivé-Marqués ¹⁹, María Álvarez del buergo ²⁰, Luisa Marena-Rojas ²¹, Carlos Fernández-López ²², Francisco Navarro ²³, E. Raya ²⁴, Eva Galindez-Agirregoikoa ²⁵, Beatriz Arca ²⁶, Roser Solans-Laqué ²⁷, Arantxa Conesa ²⁸, Cristina Hidalgo ²⁹, Carlos Vazquez ³⁰, Jose Andrés Román-Ivorra ³¹, Pau Lluch ³², Sara Manrique ³³, P. Vela ³⁴, Eugenio de Miguel ³⁵, Carmen Torres-Martín ³⁶, Juan Carlos Nieto ³⁷, Carmen Ordas-Calvo ³⁸, Eva salgado-Pérez ³⁹, Cristina Luna-Gómez ⁴⁰, F. Javier Toyos-Sáenz De Miera ⁴¹, Nagore Fernández-Llanio ⁴², Antonio García ⁴³, Elena Aurrecoechea ⁶, Norberto Ortego ⁴⁴, Francisco Ortiz-Sanjuán ³¹, Montserrat Corteguera ³⁶, Jose Luis Hernández ¹, Miguel Angel González-Gay ⁴⁵ and Ricardo Blanco ⁴⁶, ¹Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Hospital de La Princesa, Madrid, Madrid, Spain, ⁸Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ¹¹Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ¹²Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹³Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁴Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramón y Cajal, Madrid, Madrid, Spain, ¹⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ¹⁷Hospital Parc Taulí, Barcelona, Catalonia, Spain, ¹⁸Hospital General Universitario de Elda, Elda, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ²⁰Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ²¹Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ²²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²³Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, ²⁴Hospital San Cecilio, Granada, Andalucia, Spain, ²⁵Hospital de Basurto, Bilbao, Pais Vasco, Spain, ²⁶Hospital Universitario San Agustín, Avilés, Asturias, Spain, ²⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ²⁸Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, ²⁹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³⁰Hospital Miguel Servet, Zaragoza, Aragon, Spain, ³¹Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ³²Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, ³³Hospital Regional de Málaga, Málaga, Andalucia, Spain, ³⁴Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ³⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ³⁶Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁷Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, ³⁸Hospital Cabueñes, Gijón, Asturias, Spain, ³⁹Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ⁴⁰Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, ⁴¹Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, ⁴²Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, ⁴³Hospital Virgen de las Nieves, Granada, Andalucia, Spain, ⁴⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, Granada, Spain, ⁴⁵Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has been approved for the treatment of Giant Cell Arteritis (GCA). It showed to be effective to induce remission, prevent relapses and…
Abstract Number: 293 • 2019 ACR/ARP Annual Meeting
False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign
Elisa Fernández¹, Irene Monjo ², Gema Bonilla ³, Chamaida Plasencia ⁴, Maria-Eugenia Miranda-Carus ², Alejandro Balsa ⁴ and Eugenio de Miguel ⁵, ¹Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁴Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. The halo sign is an accepted valid test for the diagnosis…
Abstract Number: 2658 • 2019 ACR/ARP Annual Meeting
Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
Alicia Rodriguez-Pla¹, Lili Zhou ², Erin Ashbeck ³ and C. Kent Kwoh ⁴, ¹University of Arizona/Banner Health Medical Center, Tucson, AZ, ²The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, Tucson, AZ, ³The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, ⁴University of Arizona, Tucson, AZ
Background/Purpose: Giant cell arteritis (GCA) has traditionally been diagnosed by a combination of symptoms, clinical findings, laboratory results, and temporal artery biopsy. More recently, imaging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].